Longitudinal therapy monitoring of ALK-positive non-small cell lung cancer (copy number, cell-free DNA)

Clinical courses of non-small cell lung cancer patients with ALK rearrangements (ALK+ NSCLC) vary widely. We analyzed 271 longitudinal plasma samples from 73 patients with advanced ALK+ NSCLC treated with ALK tyrosine kinase inhibitors by combined hybrid-capture-based targeted sequencing (average 4,100x coverage) for mutation analysis and shallow whole genome sequencing (0.5x coverage) for global copy number profiling from cfDNA.

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

3 Datasets 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001006297	270 samples with ALK-positiv non-small cell lung cancer, targeted sequencing (198 kb panel size)		270
EGAD00001006298	268 samples with ALK-positiv non-small cell lung cancer, ultra-low coverage whole genome sequencing		268
EGAD00001007817	This dataset contains 538 Tumor and Control WGS and WES files for samples already submitted and published in study EGAS00001004276	Illumina HiSeq 4000 NextSeq 500	400

Publications	Citations
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. Dietz S, Christopoulos P, Yuan Z, Angeles AK, Gu L, Volckmar AL, Ogrodnik SJ, Janke F, Fratte CD, Zemojtel T, Schneider MA, Kazdal D, Endris V, Meister M, Muley T, Cecchin E, Reck M, Schlesner M, Thomas M, Stenzinger A, Sültmann H. EBioMedicine 62: 2020 103103	27